Real-world Outcomes of Trifluridine/Tipiracil With or Without Bevacizumab in Metastatic Colorectal Cancer: A Retrospective Cohort Study

医学 贝伐单抗 回顾性队列研究 内科学 肿瘤科 结直肠癌 队列研究 外科 转移 化疗 队列 梅德林 总体生存率 癌症 结肠疾病
作者
Tetsuro Kawazoe,Koji Ando,Keiichiro Ryujin,Sho Nambara,Yasuo Tsuda,Tomonori Nakanoko,Eiji Oki,Tomoharu Yoshizumi
出处
期刊:Anticancer Research [International Institute of Anticancer Research (IIAR) Conferences 1997. Athens, Greece. Abstracts]
卷期号:46 (10): 5553-5564
标识
DOI:10.21873/anticanres.18399
摘要

Background/Aim: Trifluridine/tipiracil (FTD/TPI) is an established treatment for refractory metastatic colorectal cancer (mCRC), and recent clinical trials have demonstrated improved survival with the addition of bevacizumab. However, real-world evidence regarding this combination therapy, particularly in patients previously treated with bevacizumab and its positioning in later-line treatment strategies, remains limited. Patients and Methods: We conducted a retrospective cohort study of patients with mCRC treated with FTD/TPI with or without bevacizumab at our institution. Overall survival (OS) and progression-free survival (PFS) were compared between the two groups using the Kaplan–Meier method and log-rank test. A Cox proportional hazards model was used to estimate hazard ratio (HR). Subgroup analyses were performed according to prior bevacizumab exposure. Additionally, exploratory analyses were conducted to evaluate treatment sequencing with regorafenib. Results: A total of 101 patients were included (FTD/TPI: n=42; FTD/TPI plus bevacizumab: n=59). The combination therapy was associated with significantly improved OS (HR=0.53, 95%CI=0.33-0.86, p=0.009) and PFS (HR=0.44, 95%CI=0.28-0.69, p<0.001). These associations remained significant in multivariate analyses. Subgroup analyses showed a consistent benefit of the combination therapy. In exploratory analyses, prior regorafenib use was associated with longer PFS (HR=0.32, p=0.002). Conclusion: In this real-world study, the addition of bevacizumab to FTD/TPI was associated with improved survival outcomes in patients with metastatic colorectal cancer, including those previously treated with bevacizumab. These findings support the clinical utility of FTD/TPI plus bevacizumab as an effective later-line treatment option. Further studies are warranted to clarify optimal treatment sequencing strategies.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
chen的应助被耀眼采纳,获得10
1秒前
fortuna发布了新的文献求助10
1秒前
1秒前
的的完成签到,获得积分10
1秒前
SciGPT的应助被幸运鹅采纳,获得10
1秒前
eric6717完成签到,获得积分10
1秒前
1秒前
局外人发布了新的文献求助10
2秒前
2秒前
Pheonix1998完成签到,获得积分10
2秒前
Jasper的应助被HenryRen采纳,获得10
2秒前
砡君发布了新的文献求助10
2秒前
vampv的应助被百香果采纳,获得10
2秒前
虚拟的如霜完成签到,获得积分10
2秒前
3秒前
所所的应助被yang采纳,获得10
3秒前
俊逸的棒棒糖完成签到,获得积分10
3秒前
朴实发带完成签到,获得积分10
3秒前
sufu_jony的应助被聪明威采纳,获得10
3秒前
TT完成签到 ,获得积分10
3秒前
orixero的应助被Maestro_S采纳,获得10
4秒前
邓统浩发布了新的文献求助10
4秒前
斯文败类的应助被zaq66996采纳,获得10
4秒前
曾经乌完成签到,获得积分10
5秒前
kk完成签到,获得积分10
5秒前
欢呼亦竹完成签到 ,获得积分10
5秒前
无极微光的应助被惊蛰海采纳,获得20
5秒前
why完成签到,获得积分10
5秒前
大胆的灵雁完成签到,获得积分10
6秒前
6秒前
HHHH完成签到,获得积分10
6秒前
蛀虫完成签到 ,获得积分10
7秒前
7秒前
迅速金毛完成签到,获得积分10
7秒前
图书馆完成签到,获得积分10
7秒前
8秒前
Ttttt发布了新的文献求助10
8秒前
邓统浩完成签到,获得积分10
8秒前
吃饭饭发布了新的文献求助10
8秒前
爱唱狐狸的番茄小子完成签到,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159790
求助须知:如何正确求助?哪些是违规求助? 9555224
关于积分的说明 21726021
捐赠科研通 7749765
什么是DOI,文献DOI怎么找? 3427296
关于科研通互助平台的介绍 2552375
邀请新用户注册赠送积分活动 2471654